Skip to main content
. Author manuscript; available in PMC: 2023 Jul 4.
Published in final edited form as: Clin Cancer Res. 2023 Jan 4;29(1):197–208. doi: 10.1158/1078-0432.CCR-22-1609

Figure 5. CDK4/6 or MEK inhibition improves FAK inhibition response in DGC xenografts.

Figure 5.

(A) Schematic description of in vivo experiment of SNU668 xenograft. We sacrificed one mouse in each group to obtain the tumor for IHC staining after the treatment of seven days. All mice were sacrificed at the endpoint, and the tumors were also collected. (B) Growth curve for SNU668 xenograft tumors (n=10–12) treated with vehicle control, VS-4718 (50 mg/kg, bid), palbociclib (50 mg/kg, qd), VS-6766 (0.3 mg/kg, qd), VS-4718+Palbociclib combination or VS-4718+VS-6766 combination. Treatment began on day1. Data are mean ± SEM. Statistical analysis was performed using data before day 22, ***P<0.001, ****P<0.0001, two-way ANOVA test. (C) Representative images of Ki-67, TUNEL and pERK1/2 staining of the SNU668 xenograft tumors collected at treatment day 7. Scale bar=100 μm.